Education
About Us
Working with TipRanks
Follow Us
Haemonetics Corp. (HAE)
NYSE:HAE
HAE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$55.30 - $97.97
Previous CloseN/A
Volume53.78K
Average Volume (3M)764.50K
Market Cap
$2.97B
Enterprise Value$4.83B
Total Cash (Recent Filing)$115.05M
Total Debt (Recent Filing)$16.13M
Price to Earnings (P/E)23.7
Beta0.75
Next Earnings
May 08, 2025EPS Estimate
1.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.54
Shares Outstanding50,237,465
10 Day Avg. Volume825,141
30 Day Avg. Volume764,498
Financial Highlights & Ratios
PEG Ratio9.32
Price to Book (P/B)N/A
Price to Sales (P/S)2.34
Price to Cash Flow (P/CF)18.40
P/FCF Ratio22.80
Enterprise Value/Market Cap1.63
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.99
Enterprise Value/Ebitda18.37
Forecast
1Y Price Target
$96.71Price Target Upside56.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Haemonetics News
PremiumCompany Announcements
Haemonetics Announces Key Executive Leadership Changes
PremiumCompany Announcements
Haemonetics Earnings Call: Growth Amid Challenges
---
Bulls Say, Bears Say
Bulls Say
ContractsThe announcement of new long-term contracts with two key Plasma customers helps dispel the long-standing fears of competition.
Financial PerformanceThe company delivered a 25.7% adjusted operating margin in the quarter, another data point suggesting that the company can, in fact, achieve its target of upper 20s adjusted operating margins by FY/26.
Market ShareShare gains with Grifols and Takeda are expected to provide sizable offsets by early in the next fiscal year.
Bears Say
Plasma BusinessThe plasma business declined 9.1% both on a reported basis and organically.
Stock PerformanceThe stock has seen a steady decline due to concerns like slowing base plasma collections and the rate of VASCADE XL uptake.
Vascular ClosureThe roll-out of VASCADE MVP XL was slower than expected and compounded by VASCADE slippage across coronary and peripheral procedures likely to persist near-term.
---
Ownership Overview
1.18% Insiders
46.29% Mutual Funds
0.20% Other Institutional Investors
26.87% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HAE FAQ
What was Haemonetics Corp.’s price range in the past 12 months?
Haemonetics Corp. lowest stock price was $55.30 and its highest was $97.97 in the past 12 months.
What is Haemonetics Corp.’s market cap?
Haemonetics Corp.’s market cap is $2.97B.
When is Haemonetics Corp.’s upcoming earnings report date?
Haemonetics Corp.’s upcoming earnings report date is May 08, 2025 which is in 13 days.
How were Haemonetics Corp.’s earnings last quarter?
Haemonetics Corp. released its earnings results on Feb 06, 2025. The company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.174 by $0.016.
Is Haemonetics Corp. overvalued?
According to Wall Street analysts Haemonetics Corp.’s price is currently Undervalued.
Does Haemonetics Corp. pay dividends?
Haemonetics Corp. does not currently pay dividends.
What is Haemonetics Corp.’s EPS estimate?
Haemonetics Corp.’s EPS estimate is 1.22.
How many shares outstanding does Haemonetics Corp. have?
Haemonetics Corp. has 50,237,465 shares outstanding.
What happened to Haemonetics Corp.’s price movement after its last earnings report?
Haemonetics Corp. reported an EPS of $1.19 in its last earnings report, beating expectations of $1.174. Following the earnings report the stock price went down -11.581%.
Which hedge fund is a major shareholder of Haemonetics Corp.?
Currently, no hedge funds are holding shares in HAE
---
Haemonetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$96.71 (56.19% Upside)
$96.71 (56.19% Upside)
Blogger Sentiment
Bullish
HAE Sentiment 85%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 41.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.07%
12-Months-Change
Fundamentals
Return on Equity
14.06%
Trailing 12-Months
Asset Growth
15.04%
Trailing 12-Months
Company Description
Haemonetics Corp.
Haemonetics Corporation is a global healthcare company that specializes in providing blood and plasma supplies and services. The company operates in the healthcare sector, focusing on blood management solutions that enhance patient care and improve operational efficiency in hospitals and blood centers. Haemonetics offers a range of products, including plasma collection systems, blood cell separators, and surgical blood salvage systems, catering to hospitals, blood banks, and plasma collection centers worldwide.
---
HAE Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with strong growth in the hospital and interventional technologies segments offset by declines in plasma revenue and challenges in China. The company's ability to secure new long-term agreements and record operating margins are positive signs, but the issues with cash flow and certain product lines indicate areas needing improvement.Read More>---
HAE Stock 12 Month Forecast
Average Price Target
$96.71
▲(56.19% Upside)
Technical Analysis
Best Analysts Covering HAE
1 Year
1 Year Success Rate
27/49 ratings generated profit
1 Year Average Return
+5.51%
reiterated a buy rating 3 months ago
Copying Anthony Petrone's trades and holding each position for 1 Year would result in 55.10% of your transactions generating a profit, with an average return of +5.51% per trade.
---